| |
MEN
|
WOMEN
|
|---|
| |
45–54
|
55–64
|
65–74
|
Total
|
p*
|
45–54
|
55–64
|
65–74
|
Total
|
p*
|
|---|
|
n
|
405
|
485
|
474
|
1364
| |
479
|
511
|
471
|
1461
| |
|
T2D, %
|
2.7
|
8.2
|
12.2
|
7.1
|
< 0.001
|
2.3
|
3.5
|
8.3
|
3.9
|
< 0.001
|
|
(95% CI)
|
(1.4–4.8)
|
(6.0–11.1)
|
(9.4–15.5)
|
(5.7–8.5)
| |
(1.2–4.1)
|
(2.1–5.5)
|
(6.0–11.1)
|
(2.9–4.9)
| |
|
ST2D, %
|
5.9
|
8.7
|
12.7
|
9.3
|
0.002
|
2.5
|
8.0
|
12.1
|
7.3
|
< 0.001
|
|
(95% CI)
|
(3.8–8.7)
|
(6.3–11.5)
|
(9.8–16.0)
|
(7.7–11.0)
| |
(1.3–4.3)
|
(5.8–10.7)
|
(9.3–15.4)
|
(5.9–8.7)
| |
|
TT2D, %
|
8.6
|
16.9
|
24.9
|
16.4
|
< 0.001
|
4.8
|
11.5
|
20.4
|
11.2
|
< 0.001
|
|
(95% CI)
|
(6.1–11.8)
|
(13.7–20.5)
|
(21.1–29.0)
|
(14.3–18.5)
| |
(3.1–7.1)
|
(8.9–14.6)
|
(16.8–24.3)
|
(9.6–12.8)
| |
|
IGT, %
|
7.9
|
15.1
|
23.8
|
15.5
|
< 0.001
|
10.4
|
15.1
|
25.1
|
17.0
|
< 0.001
|
|
(95% CI)
|
(5.5–11.0)
|
(12.0–18.5)
|
(20.1–27.9)
|
(13.5–17.6)
| |
(7.8–13.5)
|
(12.1–18.5)
|
(21.2–29.2)
|
(15.0–19.1)
| |
|
IFG, %
|
9.9
|
12.4
|
5.9
|
10.0
|
0.002
|
5.2
|
5.1
|
4.2
|
5.2
|
0.746
|
|
(95% CI)
|
(7.2–13.2)
|
(9.6–15.6)
|
(4.0–8.4)
|
(8.2–11.8)
| |
(3.4–7.6)
|
(3.4–7.4)
|
(2.6–6.5)
|
(3.9–6.5)
| |
|
AGT, %
|
26.4
|
44.3
|
54.6
|
42.0
|
< 0.001
|
20.5
|
31.7
|
49.7
|
33.4
|
< 0.001
|
|
(95% CI)
|
(22.2–31.0)
|
(39.9–48.9)
|
(50.0–59.2)
|
(39.2–44.8)
| |
(16.9–24.4)
|
(27.7–35.9)
|
(45.1–54.3)
|
(30.9–36.0)
| |
- *p-values are for test of equivalence (likelihood-ratio test) between the three age-groups
- Total is an estimate of the population prevalence in the age group 45–74 years, taking into account the stratified sampling used in the study.
